These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12037506)

  • 21. Vascular effects of TZDs: new implications.
    Blaschke F; Spanheimer R; Khan M; Law RE
    Vascul Pharmacol; 2006 Jul; 45(1):3-18. PubMed ID: 16740417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
    Mudaliar S; Henry RR
    Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Haffner SM; Greenberg AS; Weston WM; Chen H; Williams K; Freed MI
    Circulation; 2002 Aug; 106(6):679-84. PubMed ID: 12163427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rosiglitazone and type 2 diabetes mellitus.
    Bragg T
    Lancet; 2001 May; 357(9266):1451. PubMed ID: 11360960
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
    Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
    J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiovascular effects of the thiazolidinedione troglitazone].
    Yamada K; Kuzuya H; Nakano T
    Nihon Rinsho; 2000 Feb; 58(2):435-9. PubMed ID: 10707572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
    Szymborska-Kajanek A; Strojek K
    Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
    [No Abstract]   [Full Text] [Related]  

  • 29. [Rosiglitazone: clinical data].
    Blickle JF
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S27-33. PubMed ID: 12037505
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosiglitazone monotherapy and type 2 diabetes.
    Lawrence IG
    Diabet Med; 2001 Nov; 18 Suppl 4():6-8. PubMed ID: 11989215
    [No Abstract]   [Full Text] [Related]  

  • 32. Pioglitazone and rosiglitazone for diabetes.
    Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Hitoglou-Makedou AD; Pagkalos EM; Yovos JG; Pliakos CI; Tourkantonis AA
    Am J Hypertens; 2005 Feb; 18(2 Pt 1):227-34. PubMed ID: 15752951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.
    Ajjan RA; Grant PJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):147-58. PubMed ID: 17160909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
    Lebovitz HE; Dole JF; Patwardhan R; Rappaport EB; Freed MI;
    J Clin Endocrinol Metab; 2001 Jan; 86(1):280-8. PubMed ID: 11232013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the thiazolidinediones on cardiovascular risk factors.
    Gilling L; Suwattee P; DeSouza C; Asnani S; Fonseca V
    Am J Cardiovasc Drugs; 2002; 2(3):149-56. PubMed ID: 14727977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells.
    Nordt TK; Peter K; Bode C; Sobel BE
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1563-8. PubMed ID: 10770198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
    Edelman SV
    Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rosiglitazone decreases albuminuria in type 2 diabetic patients.
    Miyazaki Y; Cersosimo E; Triplitt C; DeFronzo RA
    Kidney Int; 2007 Dec; 72(11):1367-73. PubMed ID: 17805239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes.
    Kapoor D; Channer KS; Jones TH
    Diab Vasc Dis Res; 2008 Jun; 5(2):135-7. PubMed ID: 18537102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.